Renal Cell Carcinoma
Conditions
Keywords
autologous cytokine induced killer cells, dendritic cell, vaccine, renal cell carcinoma
Brief summary
The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.
Detailed description
The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regime. Primary 1\. Determine the clinical responses(objective response, progression-free survival, and overall survival) in patients with renal cell carcinoma treated with autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) in combination with Cytokine-Induced Killer Cell (CIK). Secondary 1. Determine cellular immune response response in terms of immuknow assay, and correlate immune response with objective clinical response in patients treated with this regimen. 2. Determine safety of multiple administrations of this regimens in these patients.
Interventions
BIOLOGICALDC-CIK
Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
DRUGIL-2/IFN-α
Patients receive treatment of IL-2 or IFN-α.
Sponsors
Fuzhou General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven renal cell carcinoma * Age: \> 18 * WHO- ECOG Performance Status 0-1 * At least one measurable tumor lesions according to the RECIST criteria. * Life expectancy more than 3 months * Written informed consent
Exclusion criteria
* Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin). * Patients with metastatic disease in the central nervous system (CNS). * Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure. * Patients with acute or chronic infection including HIV. * Patients who are pregnant or nursing. * Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial. * Patients who receive corticosteroids or other immunosuppressive agents. * Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective tumor response (complete and partial response), Time to recurrence (TTR), Progression-free(PFS) and overall survival(OS) as measured by RECIST criteria. | every 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Immunity as measured by T-cell functionality (immuknow assay )to the tumor. Safety as measured by NCI common toxicity table （CTC） at completion of study. | at screening, baseline, weeks 4 , 12 and years 1 after first vaccination, and at completion of study treatment |
Countries
China
Contacts
Primary ContactJianming Tan, Professor
Outcome results
None listed